Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AssigneeImmunoGen, Inc.
InventorsRavi V. J. Chari, Walter A. Blättler
Life of this patent
Estimating the term…
Abstract
A cytotoxic agent comprising one or more modified doxorubicins/daunorubicin linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more modified doxorubicins/daunorubicins covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more modified doxorubicins/daunorubicins linked to a cell binding agent. Novel sulfur-containing modified doxorubicins/daunorubicins.
Claims16
A compound represented by formula (I):
- wherein,
- X is H or OH;
- Y is O or NR2, wherein R2 is linear or branched alkyl having 1 to 5 carbon atoms;
- R is a linking group, H, or linear or branched alkyl having 1 to 5 carbon atoms;
- and
- R′ is a linking group, H, or —OR1, wherein R1 is linear or branched alkyl having 1 to 5 carbon atoms;
- provided that one of R and R′ is a linking group, but R and R′ are not linking groups at the same time.
A cytotoxic agent comprising one or more compounds covalently bonded to a cell binding agent through a linking group, wherein at least one of said compounds is a compound represented by formula (I):
- wherein,
- X is H or OH;
- Y is O or NR2, wherein R2 is linear or branched alkyl having 1 to 5 carbon atoms;
- R is a linking group or —CH3;
- and
- R′ is a linking group, —OCH3, or H;
- provided that one of R and R′ is a linking group, but R and R′ are not linking groups at the same time.
Dependencies are inferred from the claim text.